Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
VALEANT PHARMACEUTICALS INTERNATIONAL (VRX)
|
Add to portfolio |
|
|
|
| Price: |
$30.11
| | Metrics |
| OS: |
75.9
|
M
| |
76
|
% ROE
|
| Market cap: |
$2.29
|
B
| |
109
|
% ROIC
|
|
Net debt:
|
$962
|
M
| |
2.5
|
x Debt/EBITDA
|
|
EV:
|
$3.25
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$392
|
M
| |
8.3
|
x EV/EBITDA
|
|
EBIT
|
$296
|
M
| |
11.0
|
x EV/EBIT
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| Revenues | 830.5 | 657.0 | 689.5 | 685.1 | 823.5 | 684.3 | 686.1 | 737.1 |
| Revenue growth | 26.4% | -4.7% | 0.6% | -16.8% | 20.4% | -0.3% | -6.9% | 18.7% |
| Cost of goods sold | 193.0 | 167.9 | 158.1 | 161.0 | 222.4 | 200.5 | 184.7 | 157.0 |
| Gross profit | 637.5 | 489.1 | 531.4 | 524.0 | 601.2 | 483.7 | 501.4 | 580.1 |
| Gross margin | 76.8% | 74.4% | 77.1% | 76.5% | 73.0% | 70.7% | 73.1% | 78.7% |
| Selling, general and administrative | 255.8 | 278.0 | 292.0 | 283.6 | | | | |
| Sales and marketing | | | | | 232.3 | 196.6 | 166.7 | 164.1 |
| Research and development | 44.0 | 87.0 | 98.0 | 105.4 | 114.1 | 92.9 | 45.3 | 49.5 |
| General and administrative | | | | | 108.5 | 99.4 | 111.6 | 366.5 |
| EBITA | 303.5 | -83.5 | 113.8 | 46.4 | 145.0 | 75.4 | 177.7 | -0.1 |
| EBITA margin | 36.5% | -12.7% | 16.5% | 6.8% | 17.6% | 11.0% | 25.9% | 0.0% |
| Amortization of intangibles | 70.6 | 50.0 | 56.0 | 51.3 | 68.8 | 59.3 | 38.6 | 30.7 |
| EBIT | 232.8 | -133.5 | 57.8 | -4.9 | 76.1 | 16.1 | 139.1 | -30.8 |
| EBIT margin | 28.0% | -20.3% | 8.4% | -0.7% | 9.2% | 2.4% | 20.3% | -4.2% |
| Pre-tax income | 199.3 | -172.7 | 20.1 | 16.3 | -83.8 | -52.2 | -13.9 | 176.9 |
| Income taxes | -58.3 | 34.7 | 13.5 | 36.6 | 55.1 | 68.6 | 41.2 | 75.0 |
| Tax rate | | | 67.2% | 223.8% | | | | 42.4% |
| Earnings from continuing ops | 257.6 | -207.4 | 6.6 | -20.2 | -139.1 | -121.1 | -66.9 | 84.2 |
| Earnings from discontinued ops | 6.1 | 166.5 | -26.8 | -37.3 | | | | |
| Net income | 263.7 | -40.8 | -20.2 | -57.6 | -188.7 | -154.7 | -57.5 | -134.8 |
| Net margin | 31.8% | -6.2% | -2.9% | -8.4% | -22.9% | -22.6% | -8.4% | -18.3% |
| |
| Diluted EPS | | | | ($0.22) | ($1.52) | ($1.44) | ($0.80) | $1.00 |
| Shares outstanding (diluted) | | | | 92.9 | 91.6 | 84.1 | 83.4 | 84.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|